The Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), has officially unveiled a revised plan to reintroduce a rebate-based model for the 340B Drug Pricing Program. This strategic shift aims to replace the long-standing practice of providing upfront discounts with a system where healthcare providers pay full price for certain medications and are subsequently reimbursed via rebates. The move, announced last week, targets a specific subset of drugs and represents the federal government’s second attempt to modernize oversight within a program that has become a cornerstone of the American healthcare safety net but remains a frequent subject of intense litigation and industry debate.
The 340B program, established by Congress in 1992, was designed to allow "covered entities"—including safety-net hospitals, federal grantees, and specialized clinics—to stretch scarce federal resources as far as possible by purchasing outpatient drugs at significantly reduced prices. By obtaining these discounts, providers can expand health services to low-income, uninsured, and underinsured populations. However, the program’s rapid expansion over the last decade has led to calls for increased transparency and stricter auditing from both pharmaceutical manufacturers and federal regulators.
The Evolution of the 340B Rebate Proposal
This is not the first time HRSA has attempted to transition the 340B program toward a rebate-based model. A previous iteration of the plan was scheduled to go live on the first of this year; however, federal courts intervened and blocked its implementation before it could take effect. In those proceedings, the judiciary cited significant procedural and legal issues, suggesting that HRSA may have overstepped its statutory authority under the Administrative Procedure Act.
Despite the initial legal setback, HRSA has returned with a revised pilot program slated to commence next year. The agency contends that the rebate model is a necessary tool for "program integrity," a term often used to describe the prevention of "duplicate discounts." Duplicate discounts occur when a manufacturer provides a 340B discount on a drug that is also subject to a Medicaid rebate, a practice prohibited by federal law. HRSA argues that a rebate model allows for a more controlled verification process, ensuring that discounts are only applied to eligible outpatient prescriptions after they have been dispensed and verified.
Scope and Specifics of the New Pilot Program
The revised pilot program is notably targeted in its scope. It applies to 25 specific drugs that are tied to Medicare’s negotiated "maximum fair price" (MFP) under the Inflation Reduction Act (IRA). The list includes high-profile medications such as the blockbuster diabetes and weight-loss treatment Ozempic, the blood thinner Eliquis, the plaque psoriasis drug Otezla, and the leukemia treatment Calquence.
By linking the 340B rebate pilot to drugs affected by the IRA, the government is attempting to align two major federal drug pricing initiatives. Under the IRA, the federal government has the power to negotiate prices directly with manufacturers for certain high-expenditure drugs. HRSA’s new plan ensures that the 340B price does not conflict with or exceed the negotiated maximum fair price, using the rebate mechanism as the balancing tool.
However, industry analysts have noted a significant detail in the list of 25 drugs: none of them are currently the primary drivers of 340B spending. The largest expenses in the 340B program typically stem from high-cost specialty medications, particularly those used in oncology and immunology, such as the cancer immunotherapy Keytruda and the HIV treatment Biktarvy. Recent HRSA data highlights this disparity, showing that while specialty medications accounted for only 38% of the total 340B units purchased last year, they represented a staggering 62% of the program’s total spending. Because the pilot program currently covers drugs representing less than 5.5% of total 340B sales, its immediate financial impact on the overall market may be limited, but its potential as a precedent is immense.
Arguments for Reform: Transparency and Accountability
The central justification provided by HRSA for this shift is the need to modernize a program that has outgrown its original framework. When the 340B program was created in the early 1990s, it was a relatively small initiative focused on a limited number of clinics. Today, it has evolved into a multi-billion-dollar system involving thousands of hospitals and tens of thousands of contract pharmacies.
"As the program has grown in both size and complexity, strengthening transparency, accountability and program integrity has become increasingly important," HRSA Administrator Tom Engels said in an official statement. "This revised pilot helps modernize program oversight by improving visibility into 340B transactions while helping preserve the program’s long-term sustainability for the patients and communities it was created to serve."
Proponents of the rebate model, including many pharmaceutical manufacturing groups, argue that the current "upfront discount" system is prone to errors and lack of oversight. They contend that shifting to a rebate system allows for a "cleaner" transaction where eligibility can be confirmed via claims data before any money is returned to the provider. This, they argue, reduces the risk of diversion—where 340B drugs are given to patients who do not meet the program’s eligibility criteria.
Hospital and Provider Backlash
The reaction from the provider community has been overwhelmingly negative. Trade groups representing 340B hospitals and clinics argue that the rebate model fundamentally changes the nature of the program, shifting the financial and administrative burden from multi-billion-dollar pharmaceutical companies to cash-strapped safety-net providers.
Maureen Testoni, CEO of the trade group 340B Health, characterized the pilot as a "flawed approach" that ignores the lessons of the past. She pointed out that federal courts have already scrutinized HRSA’s legal standing to enforce such a change, suggesting that the revised plan is likely to face similar litigation. Testoni and other advocates argue that the 340B statute specifically requires manufacturers to "offer" the 340B price at the time of purchase, and that a rebate system—which requires providers to float the full cost of the drug for weeks or months—violates the spirit and letter of the law.
The American Hospital Association (AHA) has also signaled its intent to fight the pilot program. AHA CEO Rick Pollack warned that the administrative requirements of tracking every 340B claim to secure a rebate would create a "bureaucratic nightmare" for hospitals.
"The agency’s analysis dramatically understates the true costs of this program, ignoring the hundreds of millions of dollars in compliance expenses, cash-flow disruptions and operational burdens that will inevitably divert scarce resources away from patient care," Pollack said in a statement. He emphasized that for rural hospitals and small community clinics, the need to pay full price upfront could create significant cash-flow crises, potentially leading to the reduction of services or even facility closures.
Economic and Operational Implications
The operational shift from a discount to a rebate model is not merely a clerical change; it represents a significant alteration in healthcare economics. Under the current system, a hospital might buy a drug for $100 that has a list price of $1,000. Under the rebate model, that hospital must pay the full $1,000 upfront. They must then submit data to a third-party administrator or the manufacturer to prove the drug was used for a 340B-eligible patient. Only after the claim is verified—a process that can take 30 to 90 days—does the hospital receive the $900 rebate.
For a large health system, this creates a massive "float" where millions of dollars are tied up in pending rebates. For a small Rural Health Clinic (RHC) or a Federally Qualified Health Center (FQHC), this financial gap can be insurmountable. Furthermore, the cost of the technology and staff required to manage these rebate claims adds a new layer of overhead that many 340B entities are not equipped to handle.
From a broader market perspective, the 340B program has become the second-largest federal prescription drug program, trailing only Medicare Part D. In 2023, 340B sales reached an estimated $54 billion. Critics of the program’s growth argue that hospitals are using the "profit" from 340B (the difference between the discounted purchase price and the high reimbursement from private insurers) to fund general operations rather than direct patient charity care. Providers counter that without these savings, they would be unable to provide money-losing services like trauma care, oncology in rural areas, and psychiatric services.
The Road Ahead: Legal Challenges and Program Sustainability
The future of the HRSA rebate pilot remains uncertain as it heads toward a likely showdown in the federal court system. Legal experts suggest that the outcome will hinge on the interpretation of the 340B statute’s "ceiling price" language. If the courts determine that the law requires a discount at the point of sale, HRSA’s rebate model will be struck down once again. If the courts grant HRSA broader "program integrity" authority, it could signal a permanent shift in how federal drug discounts are managed.
Beyond the legal battles, the pilot program serves as a litmus test for the sustainability of the 340B program in an era of drug price negotiation. As the Inflation Reduction Act continues to roll out, the overlap between 340B and Medicare-negotiated prices will only increase. Whether the rebate model expands to include the high-cost specialty drugs that drive the majority of 340B spending will likely depend on the administrative success or failure of this initial 25-drug pilot.
For now, healthcare providers are bracing for a period of increased administrative complexity and financial uncertainty. As HRSA prepares for the 2026 launch, the healthcare industry remains divided between those who see the rebate model as a necessary step toward transparency and those who view it as an existential threat to the providers serving the nation’s most vulnerable patients.
